TY - JOUR T1 - The effects of reduced nicotine content cigarettes in smokers with mood or anxiety disorders: a double-blind randomized trial JF - medRxiv DO - 10.1101/2022.05.24.22275536 SP - 2022.05.24.22275536 AU - Jonathan Foulds AU - Susan Veldheer AU - Gladys Pachas AU - Shari Hrabovsky AU - Ahmad Hameed AU - Sophia I Allen AU - Corinne Cather AU - Nour Azzouz AU - Jessica Yingst AU - Erin Hammett AU - Jennifer Modesto AU - Nicolle M Krebs AU - Courtney Lester AU - Neil Trushin AU - Lisa Reinhart AU - Emily Wasserman AU - Junjia Zhu AU - Jason Liao AU - Joshua E Muscat AU - John P Richie, Jr AU - A Eden Evins Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275536.abstract N2 - BACKGROUND The U.S. Food and Drug Administration and the government of New Zealand have proposed a reduction of the nicotine content in cigarettes to very low levels. This study examined the likely effects of this regulation in smokers with affective disorders.METHODS In a randomized controlled trial conducted at two sites (Penn State Hershey and Massachusetts General Hospital, Boston) 188 adult smokers with a current or lifetime anxiety or unipolar mood disorder, not planning to quit in the next 6 months, were randomly assigned to smoke either Usual Nicotine Content (UNC) (11.6 mg nicotine/cigarette) cigarettes, or Reduced Nicotine Content (RNC) cigarettes where the nicotine content per cigarette was progressively reduced to 0.2 mg in five steps over 18 weeks. Participants were then offered the choice to either receive assistance to quit smoking, receive free research cigarettes, or resume using their own cigarette brand during a 12-week follow-up period. Main outcomes were biomarkers of nicotine and toxicant exposure, smoking behavior and dependence and severity of psychiatric symptoms.RESULTS After switching to the lowest nicotine content cigarettes, compared to smokers in the UNC group, the RNC group had significantly lower plasma cotinine (metabolite of nicotine), urine NNAL (metabolite of NNK, a lung carcinogen), exhaled carbon-monoxide, cigarette consumption, and cigarette dependence. There were no significant effects on psychiatric symptoms. At the end of the 12-week treatment choice phase, those randomized to the RNC group were more likely to have quit smoking (18% RNC v 4% UNC, p=0.004).CONCLUSION Reducing nicotine content in cigarettes to very low levels reduces toxicant exposure and cigarette addiction and increases smoking cessation in smokers with mood and/or anxiety disorders, without worsening mental health.Trial registration TRN: NCT01928758, registered August 21, 2013Competing Interest StatementJF has done paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer Inc (not related to reduced nicotine cigarettes). AEE reports grant support to her institution from subcontracts from NIDA grants to Charles River Analytics and Brain Solutions LLC and consulting fees from Karuna Pharmaceuticals and Alkermes and editorial support from Pfizer for papers arising from the EAGLES trial. NA currently works for Zentalis Pharmaceuticals (but did not at the time the study was conducted).There are no competing interests to declare for other authors.Clinical TrialNCT01928758Clinical Protocols https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-3946-4 Funding StatementResearch reported in this publication is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number P50DA036107 and the Center for Tobacco Products of the U.S. Food and Drug Administration. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration. Participants at the Penn State University site are seen at the Clinical Research Center supported by the Penn State Clinical & Translational Research Institute, Pennsylvania State University CTSA, NIH/NCATS Grant Number UL1 TR000127.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Penn State Hershey and Massachusetts General Hospital Institutional Review Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWith publication, requests for de-identified individual participant data and/or study documents (data dictionary, protocol, statistical analysis plan, measures/manuals/informed consent documentation) will be considered. The requestor must submit a 1-page abstract of their proposed research, including purpose, analytical plan, and dissemination plans. The Leadership Committee of the Penn State Center for Research on Tobacco and Health will review the abstract and decide based on the individual merits. Review criteria and prioritization of projects include potential of the proposed work to advance public health, qualifications of the applicant, the potential for publication, the potential for future funding, and enhancing the scientific, geographic, and demographic diversity of the research portfolio. Following abstract approval, requestors must receive institutional ethics approval or confirmation of exempt status for the proposed research. An executed data use agreement must be completed prior to data distribution. Contact is through Dr. Jonathan Foulds (jfoulds{at}psu.edu).NNAL4-(methylnitrosamino)-1-(3-pyridyl)-1-butanolNNK4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneCOcarbon monoxideDSM-5Diagnostic and Statistical Manual of Mental Disorders, 5th Edition ER -